UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): March 13, 2008
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 001-15281 | | 76-0233274 |
(State or other jurisdiction of
incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
Repros Therapeutics Inc. (the “Company”) announced today that it will report financial results for the quarter and year ended December 31, 2007, before the market opens on March 17, 2008. Repros management will hold a conference call to provide an update on the company’s progress and to answer investor questions at 12:00 noon CT on the same day. Investors can access the call by dialing 866-237-3252 (within the United States) or 719-457-1018 (International). The Passcode is 442473.
Item 9.01. Financial Statements and Exhibits
c. Exhibits
| | | |
| Exhibit | | |
| Number | | Description |
| 99.1 | | Press Release dated March 13, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
Date: March 14, 2008 | Repros Therapeutics Inc.
| |
| |
| | By: | /s/ Louis Ploth, Jr. | |
| | | Louis Ploth, Jr. | |
| | | Vice President, Business Development
and Chief Financial Officer | |
EXHIBIT INDEX
| | | |
| Exhibit | | |
| Number | | Description |
| 99.1 | | Press Release dated March 13, 2008 |
